Absci (ABSI) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Absci (ABSI) has outperformed Xencor (XNCR) over the past year, gaining 113.9% versus a gain of 97.6%. Over five years, ABSI leads with a -15.9% price change compared with -36.3% for XNCR. Xencor is the larger company by market cap ($1.87 billion vs $1.77 billion), about 1.1 times the size.
Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | XNCR |
|---|---|---|
| Share price | $10.30 | $25.14 |
| Market cap | $1.77B | $1.87B |
| 1-day change | +15.16% | +2.61% |
| YTD return | +156.16% | +60.03% |
| 1-year return | +113.88% | +97.58% |
| 5-year return | -15.90% | -36.31% |
| EPS (TTM) | $-0.79 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $125.58M |
| Revenue growth (YoY) | -38.24% | +13.65% |
| Net income (latest FY) | $-115.18M | $-91.92M |
| Operating margin | -4297.04% | -141.35% |
| Net margin | -4113.68% | -73.20% |
| 52-week high | $12.06 | $30.61 |
| 52-week low | $2.24 | $10.38 |
| Distance from 52-week high | -14.60% | -17.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +39.87% | +24.98% |
| Average volume | 3.45M | 1.32M |
| Shares outstanding | 171.61M | 74.35M |
| Employees | 140 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed XNCR by 16.3 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- Xencor grew revenue faster in its latest fiscal year (+13.65% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ABSI vs XNCR FAQ
Which is bigger, Absci or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.87B compared with $1.77B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or XNCR?
ABSI returned +113.88% over the past 12 months, compared with +97.58% for XNCR (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Xencor in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Xencor.